ArticleNature2026
In vivo site-specific engineering to reprogram T cells.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Rewiring immunity with in vivo CAR T cell engineering.Nature cancer · 2026Review
- From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy.Biomedicines · 2026Review
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- TRAC in vivo: culmination of CAR and vector engineering.Cell research · 2026Article
- Editor's pick: Stylus Medicine.Nature biotechnology · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse model.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Biotech's coming of age.Nature biotechnology · 2026Article
- Antigen-presenting nanoparticles for in vivo CAR T cell engineering.Nature reviews bioengineering · 2026Article
- Programming T cells for intercellular genome editing.bioRxiv : the preprint server for biology · 2026Article
- In Vivo CAR-Based Immune Cell Engineering: Future Applications and Challenges in Malignant Glioma.Cancers · 2026Review
- Parallel Activation and Interference CRISPR (PAIR) with Sequencing Uncovers DNA Repair Networks Guiding Precision Cell Engineering.bioRxiv : the preprint server for biology · 2026Article
- Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development.Cancer cell international · 2026Review
- Article
- Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges.Frontiers in oncology · 2026Review
- Review
- Review
- Delivery platforms forFrontiers in immunology · 2026Review
- Mechanisms of and mitigating strategies for cellular immune responses to CRISPR-associated nucleases in genome editing therapy.Frontiers in medicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
William A Nyberg *Department of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9982-1305
Pierre-Louis Bernard *Department of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6567-619X
Wayne NgoInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-5755-2303
Charlotte H WangDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7588-2077
Jonathan ArkDepartment of Molecular Genetics & Microbiology, Duke University School of Medicine, Durham, NC, USA.
Allison RothrockDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0002-6734-6180
Gina M BorgoDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Gabriella R KimmerlyDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2920-2218
Jae Hyung JungDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Vincent AllainDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Jennifer R HamiltonInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7136-1757
Alisha BaldwinGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Robert StickelsGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Sarah WymanDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Safwaan H KhanDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Shanshan LangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Donna MarshGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Niran AlmudhfarGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Catherine NovickGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Yasaman MortazaviGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Shimin ZhangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Mahmoud M AbdElwakilDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Luis R SandovalDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.
Sidney HwangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Simon N ChuDepartment of Surgery, Division of Pediatric Surgery, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3863-1548
Hyuncheol JungDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2665-0434
Chang LiuDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0003-1294-9686
Devesh SharmaDepartment of Surgery, Division of Pediatric Surgery, University of California, San Francisco, San Francisco, CA, USA.
Travis McCrearyDepartment of Surgery, Division of Pediatric Surgery, University of California, San Francisco, San Francisco, CA, USA.
Zhongmei LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Ansuman T SatpathyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5167-537X
Julia CarnevaleDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9410-7148
Rachel L RutishauserDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
M Kyle CromerGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8198-5010
Kole T RoybalDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3030-7954
Stacie E DodgsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6622-5507
Jennifer A DoudnaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Aravind AsokanDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-5563-4877
Justin EyquemDepartment of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu.ORCID http://orcid.org/0000-0001-8262-1190
Funding
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8MBD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573kNIDDK NIH HHS P30 DK063720NIH HHS S10 OD021822NIH S10 Instrumentation grant S10 1S10OD021822-0
Abstract
Engineered T cells, reprogrammed to express chimeric antigen receptors (CAR) or T cell receptors (TCR), have transformed cancer treatment and are being explored as therapeutics for autoimmune and infectious diseases. Enhancing T cell function through genome editing, either by disrupting endogenous genes or precisely inserting DNA payloads, has shown considerable promise
Indexed as
Cell EngineeringCellular ReprogrammingGene EditingT-LymphocytesAnimalsCRISPR-Cas SystemsDependovirusFemaleGenetic VectorsHumansImmunotherapy, AdoptiveMaleMiceReceptors, Chimeric AntigenTransgenesReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.